Cyfuse Biomedical KK (TSE:4892) Total Liabilities: 円1,508.40 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4892 Cyfuse Biomedical KK TSE:4892
53 GF Score
Price 円563.00
GF Value 円2,176.95
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Total Liabilities?

Cyfuse Biomedical KK TSE:4892 +2.55% 53 Total Liabilities is 円1,508.40 Mil as of Dec. 2025. GuruFocus rates TSE:4892 with a GF Score™ of 53/100 and a GF Value™ of 円2,176.95 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cyfuse Biomedical KK's Total Liabilities for the quarter that ended in Dec. 2025 was 円1,508.40 Mil.

Cyfuse Biomedical KK's quarterly Total Liabilities increased from Jun. 2025 (円901.89 Mil) to Sep. 2025 (円1,442.59 Mil) and increased from Sep. 2025 (円1,442.59 Mil) to Dec. 2025 (円1,508.40 Mil).

Cyfuse Biomedical KK's annual Total Liabilities declined from Dec. 2023 (円1,011.34 Mil) to Dec. 2024 (円975.60 Mil) but then increased from Dec. 2024 (円975.60 Mil) to Dec. 2025 (円1,508.40 Mil).

Cyfuse Biomedical KK Total Liabilities Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK Total Liabilities Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 746.12 1,045.54 1,011.34 975.60 1,508.40

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 966.53 901.89 1,442.59 1,508.40 1,344.31
TSE:4892
53GF Score
Cyfuse Biomedical KK TSE:4892
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cyfuse Biomedical KK's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=866.063+(642.336+0.00100000000009
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,508.40

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=4266.026-2757.626
=1,508.40

Cyfuse Biomedical KK's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=866.063+(642.336+0.00100000000009
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,508.40

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=4266.026-2757.626
=1,508.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円1,508.40 Mil mean?
Cyfuse Biomedical KK (TSE:4892) has a Total Liabilities of 円1,508.40 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cyfuse Biomedical KK and its competitors.
Is Cyfuse Biomedical KK's Total Liabilities too high?
Cyfuse Biomedical KK's current Total Liabilities is 円1,508.40 Mil. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Total Liabilities compare to ZTS and UTHR?
Cyfuse Biomedical KK's Total Liabilities of 円1,508.40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Cyfuse Biomedical KK and its competitors. Cyfuse Biomedical KK's current Total Liabilities is 円1,508.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,176.95, compared to a current price of 円563.00 — trading 74.1% below its estimated fair value. The current Total Liabilities is 円1,508.40 Mil. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Total Liabilities is 円1,508.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円563.00 is trading 74.1% below its estimated GF Value™ of 円2,176.95. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • Total Liabilities: 円1,508.40 Mil
  • GF Value™: 円2,176.95 vs. price of 円563.00 (74.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score

Get the complete analysis for TSE:4892

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円563.00
Price
円2,176.95
GF Value